The FDA has accepted a supplemental application from Organon to extend the duration of use for MIUDELLA, a copper IUD that Organon licensed globally earlier this year. The device is already indicated for pregnancy prevention for up to 3 years, with an extended duration review underway and commercial availability targeted for late 2026. The product sits within Organon's women's health portfolio, which anchors much of the company's current narrative. Organon's share price has had a quiet week but a strong year, with an 88.95% year to date share price return contrasted against a 30.48% total shareholder return over the past 12 months and weaker multi year outcomes. Against Organon's last close of $13.68, the most followed valuation work points to a fair value of $11.25, while the stock trades on a P/E of 17.2x versus a peer average of 20.7x and a fair ratio of 31x.
Organon & CoFDA accepted Organon's supplemental application to extend MIUDELLA's duration of use, a regulatory milestone for its women's health portfolio.
